Furthermore, MSC transplanted into a mouse model of liver failure improved the survival rate of the mice, also associated to NRF2 upregulation resulting in subsequent antioxidant activity [90], supporting the view that NRF2 might be the main actor in the mechanism by which MSC and MSC-S exert their therapeutic effects. This evidence concerns the gene NFE2L2 and liver failure.